News Sentiment

QNTM sentiment intelligence

Quantum BioPharma Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.24 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.1% over one week, -14.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Quantum BioPharma Plans to Settle Debt

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend inactive -14.7% over four weeks
Fair value -86.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 33
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 7
GlobeNewswire 6
NewMediaWire 5
Quiver Quantitative 4
TradingView 3
marketscreener.com 2
Barchart.com 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 11
Regulatory and legal 7
Balance sheet 5
Capital return 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
GlobeNewswire Direct company coverage

Quantum BioPharma Provides Corporate Update

Quantum BioPharma has revised the terms of its Debenture Units due to a decrease in the public market price of its Class B subordinate voting shares. The conversion price per share has been reduced to $3.00, the number of Warrants per Debenture Unit increased to 333.33, and the e

Tone
Negative 40/100
Event
Market update
Published
11 Mar 2026 19:11
Source
GlobeNewswire
Sahm Direct company coverage

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Grant & Eisenhofer has filed a class action lawsuit against CIBC and RBC on behalf of Quantum BioPharma shareholder Paul Durkacz, alleging stock market manipulation of Quantum BioPharma shares between January 6, 2021, and October 15, 2025. Quantum BioPharma plans to seek appointm

Tone
Negative 18/100
Event
Regulatory and legal
Published
20 Dec 2025 13:09
Source
Sahm
Stock Titan Direct company coverage

Quantum BioPharma (NASDAQ: QNTM) ends $21,225,000 ATM, settles $260,000 debt

Quantum BioPharma closed a non-brokered private placement on December 10, 2025, issuing 30 Class A shares for $750, with two related parties increasing their voting rights significantly. The company also terminated its $21,225,000 at-the-market sales agreement with H.C. Wainwrigh

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Dec 2025 22:32
Source
Stock Titan
Quiver Quantitative Direct company coverage

Quantum BioPharma Ltd. Announces Record Date for Distribution of Contingent Value Rights to Class B Subordinate Voting Shareholders

Quantum BioPharma Ltd. has set October 27, 2025, as the record date for distributing contingent value rights (CVRs) to Class B Subordinate Voting Shareholders. These CVRs will entitle shareholders to a portion of net proceeds from the company's ongoing $700 million litigation aga

Tone
Neutral 50/100
Event
Market update
Published
03 Oct 2025 11:11
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Quantum BioPharma announced October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shares holders. These CVRs will entitle holders to a pro rata portion of 10% to 50% of the net proceeds from a legal action against CIBC

Tone
Neutral 50/100
Event
Capital return
Published
03 Oct 2025 07:00
Source
GlobeNewswire
GlobeNewswire Direct company coverage

Quantum BioPharma Announces Intention to Declare Special

Quantum BioPharma (NASDAQ: QNTM) announced its intention to declare a special dividend of Contingent Value Rights (CVRs) to shareholders. These CVRs will entitle holders to a pro rata portion (10% to 50%) of net proceeds from its over $700 million lawsuit against CIBC World Marke

Tone
Positive 65/100
Event
Capital return
Published
13 Jun 2025 17:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Quantum BioPharma Shareholders to Get Up to 50% of $700M Potential Legal Settlement via Special Dividend

Quantum BioPharma (NASDAQ: QNTM) announced it plans to issue special dividend Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders, entitling them to 10-50% of net proceeds from a $700 million litigation against major banks for alleged stock price manipulatio

Tone
Positive 66/100
Event
Capital return
Published
13 Jun 2025 13:08
Source
Stock Titan
Quantisnow Direct company coverage

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

Quantum BioPharma Ltd. announced corporate updates including management changes, cancellation of 32,690 stock options, and the grant of 32,690 restricted share units (RSUs). The company also intends to settle $450,000 in bonuses for three executives into Class B Shares at a deeme

Tone
Neutral 50/100
Event
Balance sheet
Published
23 Aug 2024 19:30
Source
Quantisnow
The Canadian Securities Exchange (CSE) Direct company coverage

Quantum BioPharma Ltd. Subordinate Voting Shares

Quantum BioPharma Ltd., trading under QNTM, is a biopharmaceutical company focused on neurodegenerative and metabolic disorders, and alcohol misuse. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out an OTC product, unbuzzd™, retaining a 20.10% ow

Tone
Positive 75/100
Event
Market update
Published
15 Aug 2024 22:39
Source
The Canadian Securities Exchange (CSE)
TradingView Direct company coverage

QNTM Stock Price and Chart — CSE:QNTM

This article provides a comprehensive overview of Quantum Biopharma Ltd. (CSE: QNTM) stock, including its current price, historical performance, key financial statistics, and upcoming earnings information. It also details the company's business segments, its focus on neurodegener

Tone
Positive 63/100
Event
Earnings
Published
15 Aug 2024 04:43
Source
TradingView
TradingView Direct company coverage

Technical Analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM)

This article provides a technical analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM), detailing indicators from moving averages, oscillators, and pivots. It offers a summary of signals (neutral, buy, sell) across various timeframes and explains the co

Tone
Neutral 50/100
Event
Market update
Published
15 Aug 2024 01:40
Source
TradingView
FinancialContent Direct company coverage

Contact - The Lethbridge Herald - News and Sports from around Lethbridge

FSD Pharma Inc. (NASDAQ: HUGE) has announced plans for a share consolidation and a name change to Quantum BioPharma Ltd (QNTM). These actions, approved by shareholders, aim to help the company regain compliance with NASDAQ's minimum bid price and are awaiting NASDAQ approval to b

Tone
Neutral 50/100
Event
Regulatory and legal
Published
12 Aug 2024 09:14
Source
FinancialContent